Ovarian hyperstimulation syndrome ( OHSS ) occurs in 5-10 % of cases.
2.
But ovarian hyperstimulation syndrome may not be so rare.
3.
This is a minimally invasive procedure, but it does carry some health risks, such as ovarian hyperstimulation syndrome.
4.
Rare adverse events ( < 1 % of people ) include : baldness and / or ovarian hyperstimulation syndrome.
5.
Some patients with ovarian hyperstimulation syndrome may have mutations in the gene for FSHR, making them more sensitive to gonadotropin stimulation.
6.
On the other hand, the GnRH antagonist protocol has a lower risk of ovarian hyperstimulation syndrome ( OHSS ), which is a life-threatening complication.
7.
Findings are conflicting, but metformin treatment as a complement in IVF cycles may reduce the risk of ovarian hyperstimulation syndrome and increase live birth rates.
8.
There is no evidence for an increased risk of ovarian hyperstimulation syndrome ( OHSS ) with IVF when compared with ovarian stimulation combined with IUI.
9.
Induction of final maturation ( such as done with hCG ) may need to be withheld because of increased risk of ovarian hyperstimulation syndrome ( OHSS ).
10.
In cycles followed by oocyte donation, use of GnRH agonists instead of hCG decreases the risk of ovarian hyperstimulation syndrome with no evidence of a difference in live birth rate.
मोबाइल